- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 10 - Additional Sodium Glucose Cotransporter 2 Inhibitors in the Pipeline
Two sodium glucose cotransporter 2 (SGLT-2) inhibitors (canagliflozin and dapagliflozin) have received approval from the FDA. In this segment, Peter Salgo, MD, highlights 2 additional SGLT-2 inhibitors that are currently in the drug pipeline for the treatment of type 2 diabetes mellitus (T2DM).
Jeffrey D. Dunn, PharmD, MBA; Kari Uusinarkaus, MD, FAAFP, FNLA; Dr Salgo; and Yehuda Handelsman, MD, FACP, FACE, FNLA, discuss the need for additional SGLT-2 inhibitors and consider how the availability of more treatment options will affect the costs of treating and managing T2DM.
Together, the experts conclude that as new agents continue to emerge, it will be important to assess and compare their effectiveness in specific patient populations.
Dr Handelsman adds that treatment recommendations are expected to be updated as healthcare professionals gain new insight about the use of SGLT-2 inhibitors in clinical practice.
Maria Lopes, MD, MS, hopes that as more experience is gained in matching appropriate patients to appropriate therapies, real-world use will establish the clinical value of SGLT-2 inhibitors.
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
